폐 약물전달 시스템 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Pulmonary Drug Delivery Systems Market size is expected to reach USD 99.15 Billion in 2034 from USD 63.26 Billion (2025) growing at a CAGR of 5.12% during 2026-2034.

The global pulmonary drug delivery systems market is experiencing significant growth due to the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and other lung disorders. These systems deliver medication directly to the lungs, providing faster and more effective treatment. The rising demand for targeted therapies and non-invasive drug delivery methods is significantly driving market expansion.

Key growth drivers include increasing air pollution, rising smoking rates, and growing awareness of respiratory health. Technological advancements in inhalers and nebulizers are improving drug delivery efficiency and patient compliance. The pharmaceutical industry is also focusing on developing innovative formulations and delivery devices to enhance treatment outcomes. Additionally, the growing geriatric population is contributing to increased demand.

Looking ahead, the market is expected to grow with advancements in smart inhalers and digital health technologies. Integration with mobile apps and real-time monitoring systems will improve patient adherence and treatment effectiveness. Emerging markets will offer strong growth opportunities due to increasing healthcare access. As respiratory diseases continue to rise globally, pulmonary drug delivery systems will remain essential in modern healthcare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Inhalers
• Nebulizers
• Accessories

By Application

• Asthma
• Cystic Fibrosis
• Chronic Obstructive Pulmonary Disease (COPD)
• Allergic Rhinitis
• Pulmonary Arterial Hypertension
• Others

By End-Use

• Hospitals & Clinics
• Ambulatory Surgical Centers (ASCs)
• Home Care
• Others

COMPANIES PROFILED

• 3M, AstraZeneca, GSK plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, OMRON Healthcare Inc, PARI GmbH, Cipla
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Inhalers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Nebulizers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Accessories Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cystic Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Chronic Obstructive Pulmonary Disease (COPD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Allergic Rhinitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Pulmonary Arterial Hypertension Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Ambulatory Surgical Centers (ASCs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PULMONARY DRUG DELIVERY SYSTEMS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PULMONARY DRUG DELIVERY SYSTEMS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 3M
  • 9.2.2 AstraZeneca
  • 9.2.3 GSK Plc
  • 9.2.4 Novartis AG
  • 9.2.5 Koninklijke Philips N.V
  • 9.2.6 Boehringer Ingelheim International GmbH
  • 9.2.7 Teva Pharmaceutical Industries Ltd
  • 9.2.8 OMRON Healthcare Inc
  • 9.2.9 PARI GmbH
  • 9.2.10 Cipla